摘要
背景及目的:环磷酰胺、阿霉素、5-氟尿嘧啶方案(CAF方案)和紫杉醇、顺铂方案(TP方案)均是治疗晚期乳腺癌的有效方案,但TP方案给药复杂。我们对两组晚期乳腺癌病例进行回顾性分析,比较CAF方案及TP方案治疗晚期乳腺癌的客观疗效和不良反应。方法:经病理检查证实的晚期乳腺癌患者117例,按不同治疗方案分为CAF组和TP组,两组病例特征具可比性(P>0.05)。CAF组(66例):环磷酰胺600mg/m2,静脉推注,第1天;5-氟尿嘧啶600mg/m2,静脉滴注,第1、8天;阿霉素60mg/m2,静脉推注,第1天。TP组(51例):紫杉醇135mg/m2,静脉滴注3h,第1天;顺铂60mg/m2,静脉滴注,第2、3天。两组均以3周为1个疗程,至少接受2个疗程化疗。结果:CAF组初治病例有效率54.8%(17/31),复治病例有效率31.4%(11/35),总有效率42.4%(28/66);TP组分别为62.5%(15/24),59.3%(16/27),60.8%(31/51)。两组初治病例有效率差异无统计学意义(P>0.05,χ2检验),复治病例有效率及总有效率差异有统计学意义(P<0.05,χ2检验)。CAF组中位无进展时间7.8个月犤95%可信区间(confidenceinterval,CI)为5.3～10.8个月犦、中位生存时间17.8个月(95%CI为13.3～22.5个月);TP组分别为8.6个月(95%CI为6.5～12个月)和19个月(95%CI为15～25.5个月),两组差异均无统计学意义(P>0.05。
BACKGROUND ＆OBJECTIVE: CAF regimen [Cytoxan＋Adriamycin＋5 fluorouracil (5 FU)] and TP regimen (paclitaxel＋cisplatin) were effective to advanced breast cancer (ABC). But TP regimen was expensive and the administration was complicated. So the authors evaluated the clinical results of CAF and TP regimens. METHODS: A total of 117 ABC patients proved pathologically were divided into CAF and TP groups. Patients in both groups were well matched with baseline disease characteristics (P >0 05). CAF group (66 cases):received Cytoxan 600 mg/m2,iv drip d1,Adriamycin 60 mg/m2 iv drip d1 and 5 FU 600 mg/m2, iv drip d1,8; TP group (51 cases): received paclitaxel 135 mg/m2 by iv drip for 3 hours and cisplatin 60 mg/m2, iv drip d2～3. The treatments were repeated every 3 weeks. All patients received two cycles of the treatment at least. RESULTS: In CAF group, the response rates (RR) of the initial treatment cases, the retreatment cases, and the whole cases were 54 8％(17/31),31 4％(11/35), and 42 4％〓(28/66), respectively. The median time to progression (TTP) was 7 8 months (95％CI:5 3－10 8 months) and the median survival was 17 8 months (95％CI:13 3－22 5％). Whereas in TP group, the RR of the initial treatment cases, the retreatment cases, and the whole cases were 62 5％(15/24), 59 3％(16/27), and 60 8％(31/51), respectively. The median TTP and the median survival were 8 6 months (95％CI:6 5－12 months) and 19 months (95％CI:15－25 5 months), respectively. There were significant differences between two groups in the RR of retreatment cases and the whole cases (P< 0 05,Chi square test). However, there was no significant difference in the RR of the initial treatment cases, the median TTP and median survival (for RR, P >0 05, Chi square test; for median TTP and median survival, P >0 05, Log rank test). Diarrhea was more serious in CAF group than in TP group; however, myodynia, peripheral neuropathy,and skin exanthem were more serious in TP group than in CAF group(P< 0 05,Wilcoxon rank sum test).There was no significant difference in the other side effects between the two groups. All side effects were tolerable. CONCLUSION: CAF regimen was still a firstly selected regimen for the patients with ABC.
出处
《癌症》
SCIE
CAS
CSCD
北大核心
2003年第4期411-414,共4页
Chinese Journal of Cancer
关键词
乳腺肿瘤
药物疗法
紫杉醇
阿霉素
联合用药
Advanced breast cancer (ABC)
Chemotherapy
Paclitaxel
Adriamycin
